There's been a theme with the inhibitors of the epidermal growth factor receptor (EGFR) -- both oral tyrosine kinase inhibitors (TKIs) and IV...
Here's a brief video just discussing the rationale for why a systemic treatment like chemotherapy is recommended not only as the cornerstone of...
Here's a brief video on the basic premise of treating locally advanced non-small cell lung cancer. [powerpress] I'll plan to do others in which I'll...
To close out the year, we're going to do our last webinar as part of our ongoing partnership with LUNGevity Foundation on the topic of small cell lung...
I would like to share with all of you an article on one of my patients that was featured in the November 2012 issue of Ladies Home Journal. I think...
Dr. David Spigel, Sarah Cannon Cancer Center, gives his view on more widespread availability of new mutation tests.
[powerpress]
Dr. Heather Wakelee, from Stanford University, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
[powerpress]
Dr. Greg Riely, from Memorial Sloan-Kettering, expresses his practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
[powerpress]
Dr. Karen Kelly, of the University of California, Davis, reviews her thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.
[powerpress]
Dr. Phil Bonomi, from Rush University, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.
[powerpress]
Dr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
[powerpress]
Dr. Rosalyn Juergens, McMaster University, discusses the question of widespread availability of new mutation tests under the Canadian health care system.
[powerpress]
Dr. Sarah Goldberg from Yale Cancer Center describes which molecular markers she seeks for NSCLC patients.
[powerpress]
Earlier this week, the FDA approved the oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tarceva (erlotinib) for the approximately 10% of advanced NSCLC patients with an activating EGFR mutation in North America and Europe (approximately 30% in Asia).
Dr. Heather Wakelee, from Stanford University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.
[powerpress]
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.